Physician profile
Howard Charles
NPI 1427078310
$2,120.60
in general payments reported to CMS, 2019-2025
12 companies · $244 in 2025
The $244 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $642 · 2020: $71.33 · 2021: $39.27 · 2022: $572 · 2023: $24.56 · 2024: $527 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $796.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $795.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $546.68 | 2019-2025 | Eylea Hd |
| Genentech USA, INC. | $481.64 | 2019-2022 | |
| Astellas Pharma US INC | $211.84 | 2024 | Izervay |
| Alcon Vision LLC | $175.93 | 2021-2025 | Rhopressa, Rocklatan |
| Abbvie INC. | $149.56 | 2023-2024 | Durysta |
| Horizon Therapeutics Plc | $125.00 | 2022 | |
| Oyster Point Pharma, INC. | $125.00 | 2024 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $124.96 | 2019-2020 | |
| Notal Vision, INC. | $117.08 | 2022 | |
| Allergan, INC. | $28.71 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $21.44 | 2024 | Miebo |
| Mallinckrodt Enterprises LLC | $12.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Charles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.